Immunoprecise Antibodies Ltd
NASDAQ:HYFT

Watchlist Manager
Immunoprecise Antibodies Ltd Logo
Immunoprecise Antibodies Ltd
NASDAQ:HYFT
Watchlist
Price: 1.7 USD -1.16% Market Closed
Market Cap: 78.5m USD

Intrinsic Value

The intrinsic value of one HYFT stock under the Base Case scenario is 1.57 USD. Compared to the current market price of 1.7 USD, Immunoprecise Antibodies Ltd is Overvalued by 7%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

HYFT Intrinsic Value
1.57 USD
Overvaluation 7%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Immunoprecise Antibodies Ltd

What is Valuation History?
Ask AI Assistant
What other research platforms think about HYFT?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is HYFT valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Immunoprecise Antibodies Ltd.

Explain Valuation
Compare HYFT to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about HYFT?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Immunoprecise Antibodies Ltd

Current Assets 21.7m
Cash & Short-Term Investments 16.5m
Receivables 4.2m
Other Current Assets 1m
Non-Current Assets 4.4m
PP&E 4.2m
Other Non-Current Assets 154k
Current Liabilities 5.2m
Accounts Payable 3.4m
Other Current Liabilities 1.8m
Non-Current Liabilities 3.2m
Long-Term Debt 3.2m
Efficiency

Free Cash Flow Analysis
Immunoprecise Antibodies Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Immunoprecise Antibodies Ltd

Revenue
20.4m CAD
Cost of Revenue
-8.5m CAD
Gross Profit
11.9m CAD
Operating Expenses
-44.8m CAD
Operating Income
-32.9m CAD
Other Expenses
3m CAD
Net Income
-29.8m CAD
Fundamental Scores

HYFT Profitability Score
Profitability Due Diligence

Immunoprecise Antibodies Ltd's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin
Strong 3Y Average Gross Margin
Gross Margin is Increasing
Declining Net Margin
15/100
Profitability
Score

Immunoprecise Antibodies Ltd's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

HYFT Solvency Score
Solvency Due Diligence

Immunoprecise Antibodies Ltd's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
64/100
Solvency
Score

Immunoprecise Antibodies Ltd's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HYFT Price Targets Summary
Immunoprecise Antibodies Ltd

Wall Street analysts forecast HYFT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HYFT is 4.08 USD with a low forecast of 3.03 USD and a high forecast of 5.25 USD.

Lowest
Price Target
3.03 USD
78% Upside
Average
Price Target
4.08 USD
140% Upside
Highest
Price Target
5.25 USD
209% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Immunoprecise Antibodies Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for HYFT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one HYFT stock?

The intrinsic value of one HYFT stock under the Base Case scenario is 1.57 USD.

Is HYFT stock undervalued or overvalued?

Compared to the current market price of 1.7 USD, Immunoprecise Antibodies Ltd is Overvalued by 7%.

Back to Top